Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 16/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 15/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.50 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22008400 | 0.94 | ITGAV (0.51) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL20480988 | 0.94 | ITGAV (0.51) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL22008399 | 0.94 | ITGAV (0.51) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL20481090 | 0.93 | ITGAV (0.52) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL30335853 | 0.92 | ITGAV (0.52) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL7094539 | 0.90 | ITGAV (0.53) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL7095811 | 0.89 | ITGB3 (0.52) | ITGAVITGB3ITGB5ITGB1ITGA2B | |
| SCHEMBL20481236 | 0.88 | ITGAV (0.49) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL22009048 | 0.87 | ITGAV (0.47) | ITGAVITGB3ITGB5ITGB1ITGB6 | |
| SCHEMBL20481335 | 0.86 | ITGAV (0.48) | ITGAVITGB3ITGB5ITGB1ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6358970-B1 | FOR THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER, AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-03-19 | — | — | US | claimed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2021-09-09 | — | — | US | disclosed |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-1194151-A4 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-01-15 | — | — | EP | disclosed |
| EP-1194151-A1 | INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6358970-B1 | FOR THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, AND INHIBITING VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, ATHEROSCLEROSIS, INFLAMMATION, ARTHRITIS, VIRAL DISEASE, CANCER, AND METASTATIC TUMOR GROWTH | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| WO-2000078317-A1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276975-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB5 15/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 12/4885ITGB5 15/4885 |
| US-20200157075-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB5 15/4885 |
| US-11040955-B2 | Inhibitors of (alpha-v)(beta-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 11/4885ITGB5 15/4885 |
| US-11046669-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | ITGAV 3/4885ITGB3 12/4885ITGB5 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.